Evidence map›Paper›PMID 34155340›Full record

ArticleBritish journal of cancer2021

Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

Hanna T Sjoberg, Yiannis Philippou, Anette L Magnussen, Iain D C Tullis, Esther Bridges, Andrea Chatrian, Joel Lefebvre, Ka Ho Tam, Emma A Murphy, Jens Rittscher and 18 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Chlorophylls: A Personal Snapshot.Molecules (Basel, Switzerland) · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 3 countries.

Hanna T Sjoberg *Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Yiannis Philippou *Department of Oncology, University of Oxford, Oxford, UK.
Anette L MagnussenNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Iain D C TullisDepartment of Oncology, University of Oxford, Oxford, UK.
Esther BridgesDepartment of Oncology, University of Oxford, Oxford, UK.
Andrea ChatrianInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Joel LefebvreInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Ka Ho TamInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Emma A MurphyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Jens RittscherInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Dina PreiseDepartment of Core Facilities, The Weizmann Institute of Science, Rehovot, Israel.
Lilach AgemyDepartment of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel.
Tamar YechezkelDepartment of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel.
Sean C SmartDepartment of Oncology, University of Oxford, Oxford, UK.
Paul KincheshDepartment of Oncology, University of Oxford, Oxford, UK.
Stuart GilchristDepartment of Oncology, University of Oxford, Oxford, UK.
Danny P AllenDepartment of Oncology, University of Oxford, Oxford, UK.
David A ScheiblinOptical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-5505-2540
Stephen J LockettOptical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
David A WinkCancer and Inflammation Program, Centre for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Alastair D LambNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2968-7155
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5347-5083
Adrian HarrisDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1376-8409
Ruth J MuschelDepartment of Oncology, University of Oxford, Oxford, UK.
Boris VojnovicDepartment of Oncology, University of Oxford, Oxford, UK.
Avigdor ScherzDepartment of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Richard J BryantNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. richard.bryant@nds.ox.ac.uk.ORCID http://orcid.org/0000-0002-8330-9251
University of Oxford · GBWeizmann Institute of Science · ILLeidos (United States) · USNational Institutes of Health · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Redox Mechanism Process of Nos2 and COX2 in Stroma tumor interactionZIABC010898 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINK, DAVID · 2009 to 2025
$8.6M
Nitric Oxide as a Modifier of Oxidative StressZIASC007281 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WINK, DAVID · 2009 to 2025
$8.1M
Properties of redox modified NSAIDs in cancer prevention and treatmentZIABC010899 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINK, DAVID · 2009 to 2025
$6.7M
Cancer Research UK 22748Cancer Research UK 25812NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

backgroundThere is a need to improve the treatment of prostate cancer (PCa) and reduce treatment side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy for low-risk low-volume localised PCa, which rapidly disrupts targeted tumour vessels. There is interest in expanding the use of VTP to higher-risk disease. Tumour vasculature is characterised by vessel immaturity, increased permeability, aberrant branching and inefficient flow. FRT alters the tumour microenvironment and promotes transient 'vascular normalisation'. We hypothesised that multimodality therapy combining fractionated radiotherapy (FRT) and VTP could improve PCa tumour control compared against monotherapy with FRT or VTP.

methodsWe investigated whether sequential delivery of FRT followed by VTP 7 days later improves flank TRAMP-C1 PCa tumour allograft control compared to monotherapy with FRT or VTP.

resultsFRT induced 'vascular normalisation' changes in PCa flank tumour allografts, improving vascular function as demonstrated using dynamic contrast-enhanced magnetic resonance imaging. FRT followed by VTP significantly delayed tumour growth in flank PCa allograft pre-clinical models, compared with monotherapy with FRT or VTP, and improved overall survival.

conclusionCombining FRT and VTP may be a promising multimodal approach in PCa therapy. This provides proof-of-concept for this multimodality treatment to inform early phase clinical trials.

Indexed as

AnimalsCell Line, TumorCombined Modality TherapyDose Fractionation, RadiationHumansHuman Umbilical Vein Endothelial CellsMaleMiceNeovascularization, PathologicPhotochemotherapyProstatic NeoplasmsSurvival AnalysisTumor MicroenvironmentXenograft Model Antitumor Assays

Identifiers

PMID34155340
PMCPMC8367986
OpenAlexW3175926434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.